Evaluation and Management of Resistant Hypertension: Core Curriculum 2024.

Am J Kidney Dis

Division of Nephrology (JHW), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Complex Hypertension Clinic (JLC, JHW), Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address:

Published: September 2024

AI Article Synopsis

  • Resistant hypertension is characterized by high blood pressure that persists despite the use of three first-line medications or requiring four or more medications at maximum doses, necessitating accurate measurements to rule out white coat syndrome.
  • It poses a greater risk for cardiovascular issues and may involve treatable secondary causes, highlighting the need for lifestyle changes and addressing medication adherence challenges.
  • Treatment should prioritize effective, long-acting medications, consider underlying causes, and involve a multidisciplinary team approach, with new therapies being researched for future management.

Article Abstract

Resistant hypertension is defined as blood pressure above goal despite confirmed adherence to 3 first-line antihypertensive agents or when blood pressure is controlled with 4 or more medications at maximal or maximally tolerated doses. In addition to meeting these criteria, identifying patients with true resistant hypertension requires both accurate in-office blood pressure measurement as well as excluding white coat effects through out-of-office blood pressure measurements. Patients with resistant hypertension are at higher risk for adverse cardiovascular events and are more likely to have a potentially treatable secondary cause contributing to their hypertension. Effective treatment of resistant hypertension includes ongoing lifestyle modifications and collaboration with patients to detect and address barriers to optimal medication adherence. Pharmacologic treatment should prioritize optimizing first-line, once daily, longer acting medications followed by the stepwise addition of second-, third-, and fourth-line agents as tolerated. Physicians should systematically evaluate for and address any underlying secondary causes. A coordinated, multidisciplinary team approach including clinicians with experience in treating resistant hypertension is essential. New treatment options, including both pharmacologic and device-based therapies, have recently been approved, and more are in the pipeline; their optimal role in the management of resistant hypertension is an area of ongoing research.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2024.04.009DOI Listing

Publication Analysis

Top Keywords

resistant hypertension
28
blood pressure
16
management resistant
8
hypertension
8
resistant
7
evaluation management
4
hypertension core
4
core curriculum
4
curriculum 2024
4
2024 resistant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!